Form 4 Filing for MoonLake Immunotherapeutics

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, reported a sale of 1100 Class A ordinary shares on July 27, 2026, at a price of $20.00 per share. This transaction was executed pursuant to a Rule 10b5-1 trading plan. Following the transaction, Reich has 35,389 shares directly owned and 2,711,198 shares indirectly owned. The filing also notes that Dr. Reich may be deemed the indirect beneficial owner of shares owned by JeruCON Beratungsgesellschaft mbH.